ADXS Stock, Advaxis Information

Advaxis is a clinical stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio engineered to secrete an antigen/adjuvant fusion protein s that is designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself. ADXS HPV is currently being evaluated in four clinical trials for human papillomavirus HPV associated cancers: recurrent/refractory cervical cancer India , locally advanced cervical cancer GOG/NCI U.S. study, Clinical Trials.gov Identifier NCT , head amp neck cancer CRUK study, Clinical Trials.gov Identifier NCT , and anal cancer BrUOG study, Clinical Trials.gov Identifier NCT . Advaxis has over distinct immunotherapies in various stages of development, developed directly by Advaxis and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.